Enhancing Radiotherapy Outcomes for Oesophageal Cancer
Supervisors:
Project Details:
Inhibition of ATR (a DNA damage checkpoint kinase) is currently being evaluated with radiotherapy and chemoradiation in patients with oesophageal cancer in the Cancer Research UK/MRC funded CHARIOT clinical study, whilst dose escalation is being evaluated in the SCOPE 2 clinical study. We have done initial in silico planning to show that protons significantly reduce the dose received by heart and lung and dose modelling to predict toxicity of dose escalation. Furthermore we have shown that heart substructures have a critical role in non-cancer related mortality. The aims of this project are:
- to evaluate acute and late lung and cardiac toxicity based on the radiobiological dose modelling.
- to optimise the radiotherapy delivery strategy in the pre-operative and definitive settings for oesophageal malignancies when MRI Linac or protons are used, particularly when novel radiation sensitisers or immune modulators are incorporated into the treatment paradigm.
The ideal applicant will have a background in radiation oncology, understanding of imaging in radiation oncology and radiotherapy planning.
Key Dates for October 2021 Entry
Applications for October 2021 entry are now open.
Deadline for applications is midday Friday 8 January 2021.
Applications received after this deadline may be considered for a place if places are still available but cannot be considered for University funding.
Please refer to our individual course pages to check the admissions status of each course.
Contact Us
Tel: +44 (0)1865 617410
Email: graduate.studies@oncology.ox.ac.uk
Due to Covid-19, please use primarily email as staff may not have access to telephones.
Latest news
Hidden lung damage from COVID-19 revealed in new study
2 December 2020
Professor Sibson secures further MRC DPFS funding
20 October 2020
Department of Oncology secures Athena SWAN Silver award
16 October 2020